SLC5A2 and atrial fibrillation: Meta-analysis of high-dose versus low-dose SGLT2 inhibitors showed no statistically significant difference in the risk of AF/AFL (RR 0.78; 95%CI, 0.60–1.02; I2 = 0%; P = 0.07), although a decreasing trend was observed in the high-dose group (Figure 4).